Professional Marketing briefs

Share this article:
Bausch & Lomb named Daniel Wechsler corporate VP and global president, pharma business. Wechsler joins Bausch & Lomb from Merck, where he was head of US strategy, commercial model innovation and business development.

Allergan has a superiority complex when it comes to marketing its ophthalmic drops, as evidenced by a second DDMAC Untitled Letter posted online. This time, a direct mail piece targeting physicians made unsubstantiated superiority claims about Lumigan, an eye drop indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The mailer paired Lumigan against latanoprost—the active ingredient in Pfizer's Xalatan.

GSK's sales force is number one with office-based primary care physicians, according to an SDI survey. Pfizer placed second and Merck placed third. Pfizer reps called most often on physicians, followed by reps from Merck, AstraZeneca, GSK and Forest. GSK calls decreased 12% in the 12 months to September over the same period last year. The products most often discussed in GSK calls included Advair, Lovaza and Avodart, docs reported.
Share this article:

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...